Search Orphan Drug Designations and Approvals
-
Generic Name: | idelalisib | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Zydelig | ||||||||||||||||
Date Designated: | 10/15/2013 | ||||||||||||||||
Orphan Designation: | Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Gilead Sciences, Inc. 199 E. Blaine St Seattle, Washington 98102 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | idelalisib |
---|---|---|
Trade Name: | Zydelig | |
Marketing Approval Date: | 07/23/2014 | |
Approved Labeled Indication: | Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. | |
Exclusivity End Date: | 07/23/2021 | |
Exclusivity Protected Indication* : | (1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-